Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC)

Released on J-STAGE: September 17, 2025 | Volume 19 Issue 4 Pages 275-276

Chenru Zhao, Daoran Lu, Jianjun Gao

Efficacy and safety of filgotinib versus tocilizumab in active rheumatoid arthritis: A randomized, open-label, multicenter study with clinical and musculoskeletal ultrasound evaluation (TRANSFORM study)

Released on J-STAGE: April 27, 2026 | Article ID 2026.01008

Toshimasa Shimizu, Shin-ya Kawashiri, Tomohiro Koga, Rieko Kiya, Michiko Morita, Rina Kawasaki, Shohei Kuroda, Shigeki Tashiro, Shuntaro Sato, Moemi Yabe, Kenta Misaki, Shunichiro Hanai, Daiki Nakagomi, Michihiro Ogasawara, Naoto Tamura, Rina Watanabe, Hiroshi Kanazawa, Tatsuya Atsumi, Yukitaka Ueki, Tadashi Okano, Takahisa Suzuki, Hirokazu Takaoka, Hiroaki Hamada, Toshihiko Hidaka, Shunsuke Furuta, Naoki Hosogaya, Hiroshi Yamamoto, Atsushi Kawakami

Telisotuzumab vedotin: The first-in-class c-Met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC)

Released on J-STAGE: July 11, 2025 | Article ID 2025.01058

Chenru Zhao, Daoran Lu, Jianjun Gao

Equivalence in the modernization of Chinese medicine: A multi-dimensional analysis of active components, processing methods, and clinical outcomes in formula granules

Released on J-STAGE: February 27, 2026 | Article ID 2025.01134

Bo Xie, Xi Qu, Huijing Shi, Yi Zhou, Dan Deng, Yuanru Liu, Rong Jiang, Ling Wang

Can the herpes zoster vaccination be a strategy against dementia?

Released on J-STAGE: May 09, 2025 | Volume 19 Issue 2 Pages 124-128

Ya-nan Ma, Kenji Karako, Peipei Song, Ying Xia